The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Emerald Carrots,
Your question, why does so and so keep posting...
Your answer:
Provocateur
Meaning of provocateur in English someone who intentionally causes arguments or discussions, or intentionally makes other people feel angry, offended, or uncomfortable: He is a provocateur not afraid of confronting his own audience.
Now a foundational rule of communication between two parties: transactions will continue indefinitely as long as transactions are complimentary. This is to say that whether you are wishing each other a good day or arguing about the time of day, each are definitions of complimentary transactions. In other words, as long as you feel the need to explain, they feel the need to provoke, or either one of you or both wants to have the last word then this ongoing transaction will continue, and unfortunately for the rest of us, it looks like it will continue indefinitely...
Good day to you both.
If you do not wish to take part in a transaction with any particular party, you do not have to
We should remember that this is not just Moditope vs cancer. The setting in which this contest takes place is the human body. So until time is called there is all to play for and we should remember that it is the body itself will have an enormous influence on outcomes and not just the drug or cancer. It is not just straight win or lose imo.
We know that Scancell were looking for a partner for Covidity. It is my opinion that they may have reached a dead end or they have been lucid enough to switch focus to SCOPE and MODIFY. Is it possible that Texas Biomed were simply offered or requested a development opportunity. If only for research purposes? May not be a dead duck after all and could be one for the long distant future.
Just tried to call Scancell to inform them that people are not getting replies to email inquiries. Also to suggest they do a test email from the website etc to source any problems. Called the number from google maps ending 069 and it went direct to a mobile - call time 9.35am today.
Bantham,
Your trouble is you can only see the tactics which is a very small subset of investing. Also, discussing them among, well, what? Your peers? Are you looking for validation? More upticks, does that mean you are on the right track to you?
You know, if you and TGTD stopped your running commentary nothing would change. You simply have no effect on the world so might you both find something else to do.
Hi violindog,
In order for the share price to appreciate we need great news and a fair market. The SCIB1 news is already outstanding but the market is dead to it. Scancell just have to keep on keeping on. If the markets corrected tomorrow we would be at 24p imo without further news. It could be argued that taking a deal at this stage will get Scancell only half the money it is due...
Annual company updates are a must. As and when updates are not enough as they are matter of fact and do not explain context and intended direction of travel etc. With innovative science and developments such as Scancell's and an apparent ability to problem solve I am sure Lindy and Co cannot wait to let us know how the last year has gone in a bit more detail. After all, last years meeting was bonza, strange to follow the next year with nowt!
Fact no1 Deal with MidAtlantic/Solaris Health - Prostate Study - May 22
Fact no 2 Second secured contract from pharma services customer - June 22
Fact No3 Paying collaboration with Bioview - Her2 Assay - April 23
Fact No4 Deal with Crescendo Biologics - Pharma Services - April 23
Fact No5 Deal with Artios - Pharma Services - May 23
As it stands four of these are payers between May 22 and May 23... and the other with MidAtlantic/Solaris should be at some point. We don't know exactly how much each contract is worth and certainly we do not know the contribution (which is far more important). We also do not know which contracts fall into which period. So to save messing about lets carry out a simple exponential growth exercise:
Based on four contracts in year one:
50% growth by year two (2024) = six contracts. Same growth for year three (2025)= nine contracts
150% growth by year two (2024) = ten contracts. Same growth for year two (2025) = twenty five contracts
So now all you need to do is fill in the gaps. Whatever you think the average revenue and contribution is.
What TGTD and others are suggesting is that there will no growth: that is to say that sales remain the same or diminish, and that the cash runs out unless there is a dilutative raise. Whilst this is possible, the facts above demonstrate that deals have been done (fact: see above) and on that basis it is reasonable to assume that they will continue to be done in the future. Not only that, but as more products and services have come on line (another fact) that sales will increase. This is reasonable IMO.
As I say, fill in the gaps. But whatever your opinion, try and be objective.
Page 15!of the presentation and 21mins and 20 seconds into the recent webcast Sept 23.
https://webcast.openbriefing.com/angle-sep23/
Cannot find a study protocol. Can anyone help?
RP,
They seem to be hitting duration of response too. 25 weeks, 37 weeks. The picture is becoming more convincing and I can only imagine it will continue. Seem to be hitting outcome measures